Pluristem Therapeutics (PSTI) receives FDA orphan status for aplastic anemia treatment
- Top 10 News for 03/23 - 03/27: Kraft/Heinz Mega Food Merger, SanDisk Warns, Biotech Bubblicious
- Intel (INTC) in Talks to Buy Altera Corp (ALTR) - WSJ
- Dow Chemical (DOW) to Separate Chlor-Alkali Unit, Merge it with Olin (OLN)
- UPDATE: BlackBerry (BBRY) Posts Q4 adj.-EPS of 4c
- Unusual 11 Mid-Day Movers 03/27: Higher GBSN, OLN, OXM; Lower OHRP, MOLG, APDN (more...)
Pluristem Therapeutics, Inc. (NASDAQ: PSTI) has received FDA orphan status for aplastic anemia treatment.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pluristem Therapeutics (PSTI) Updates on PLX-R18 Development Strategy
- Northwest Biotherapeutics (NWBO) Reports Survival Data from DCVax®-L Study
- Novo Nordisk (NVO) Will Submit Prespecified Interim Analysis of DEVOTE as Part of Resubmitted Tresiba, Ryzodeg NDA
Create E-mail Alert Related CategoriesFDA, Insiders' Blog
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!